Signals via API

Public sample from today's flagship detail endpoint. Public payloads can be limited or redacted. The backend exposes read endpoints for signals, storylines, and briefings.

GET /v1/narratives/f41a6b13-7bbd-4d02-938a-e1ad958c64c9?tenant=biotech&run_id=95e62395-9529-470f-b806-302c8d8781d5

{
  "id": "f41a6b13-7bbd-4d02-938a-e1ad958c64c9",
  "title": "Jeito closes 'record' $1.2bn Europe-focused biopharma fund",
  "summary": "Jeito closes 'record' $1.2bn Europe-focused biopharma fund Phil.Taylor Wed, 08/04/2026 - 11:16",
  "first_seen_at": "2026-04-08T10:08:21.473525Z",
  "last_seen_at": "2026-04-08T15:23:00Z",
  "created_at": "2026-04-08T17:06:12.170078Z",
  "updated_at": "2026-04-09T05:06:01.792411Z",
  "timeframe": "24h",
  "run_id": "95e62395-9529-470f-b806-302c8d8781d5",
  "metrics": {
    "divergence": 3.1623,
    "post_count": 3,
    "momentum_1h": 0,
    "momentum_7d": 3,
    "score_total": 1.302311,
    "shill_score": 10,
    "momentum_24h": 3,
    "market_movers": [],
    "evidence_score": 0.75,
    "unique_authors": 3,
    "coherence_score": 0.8222,
    "diversity_bonus": 0.1625,
    "duplicate_ratio": 0,
    "platforms_count": 1,
    "social_momentum": 3,
    "divergence_label": "chatter_without_pricing",
    "market_conviction": 0,
    "origin_share_top1": 0.333333,
    "unique_publishers": 3,
    "origin_layer_posts": 0,
    "source_types_count": 1,
    "unique_authors_24h": 3,
    "unique_origin_urls": 3,
    "amplifier_share_top1": 0.333333,
    "author_concentration": 0.3333,
    "publisher_share_top1": 0.333333,
    "amplifier_layer_posts": 3,
    "concentration_penalty": 0,
    "unique_origin_domains": 3,
    "source_diversity_bonus": 0,
    "unique_publisher_types": 1,
    "unique_origin_publishers": 3
  },
  "platforms": [
    "rss"
  ],
  "top_tickers": [],
  "why_now": [],
  "display_title": "Jeito Capital closes record $1.2 billion fund for European biopharma",
  "display_summary": "Jeito Capital has raised $1.2 billion, marking the largest ever fund by an independent European biopharma-focused venture firm. The capital will support 15 to 20 clinical-stage biopharma companies, reinforcing Jeito's role as a leading biotech investor in Europe.",
  "narrative_frame_display": "Jeito Capital has secured $1.2 billion in funding, the largest raise ever for an independent European biopharma-focused venture fund. This new capital will back 15 to 20 clinical-stage biopharma companies, highlighting strong investor confidence in European biotech innovation and positioning Jeito as a key player in advancing clinical-stage drug development across the region.",
  "entities": {
    "companies": [
      "Jeito Capital"
    ]
  },
  "recurring_claims": [
    {
      "claim": "Jeito Capital raised $1.2 billion, the largest fund ever by an independent European biopharma-focused venture firm.",
      "evidence_urls": [
        "https://biopharmadive.com/news/jeito-capital-biopharma-venture-fund-billion/816946",
        "https://fiercebiotech.com/biotech/jeito-hails-12b-largest-raise-ever-independent-biopharma-focused-european-fund",
        "https://pharmaphorum.com/news/jeito-closes-record-12bn-europe-focused-biopharma-fund"
      ]
    },
    {
      "claim": "The fund will support 15 to 20 clinical-stage biopharma companies, accelerating drug development in Europe.",
      "evidence_urls": [
        "https://biopharmadive.com/news/jeito-capital-biopharma-venture-fund-billion/816946"
      ]
    }
  ],
  "stance_map": [
    {
      "stance": "promotes",
      "who": "Jeito Capital",
      "evidence_urls": [
        "https://biopharmadive.com/news/jeito-capital-biopharma-venture-fund-billion/816946"
      ]
    }
  ],
  "quality_flags": {
    "mixed_topic_risk": "low",
    "promo_risk": "low",
    "source_quality": "high"
  },
  "editor_note": null,
  "display_tags": [
    "biotech_funding",
    "clinical_trials",
    "drug_development",
    "r_and_d"
  ],
  "tags": [
    "biotech_funding",
    "clinical_trials",
    "drug_development",
    "r_and_d"
  ],
  "cscope_tags": [
    "biotech_funding",
    "clinical_trials",
    "drug_development",
    "r_and_d"
  ],
  "why_now_display": [
    "The fund closing reflects growing momentum and capital flow into European biopharma amid a competitive global biotech investment landscape.",
    "Jeito aims to capitalize on emerging clinical-stage opportunities in Europe with substantial new resources.",
    "This milestone sets a new benchmark for independent biopharma-focused funds in Europe, attracting further investor interest."
  ],
  "why_it_matters_display": [
    "Largest independent European biopharma fund signals strong investor confidence in clinical-stage biotech innovation.",
    "The fund will accelerate development of 15 to 20 clinical-stage biopharma companies, potentially advancing new therapies.",
    "Jeito's record raise may influence competitive dynamics in European biotech venture funding."
  ],
  "show_why": true,
  "sources_display": [
    {
      "label": "biopharmadive.com: BioPharma Dive"
    },
    {
      "label": "pharmaphorum: Jeito closes 'record' $1.2bn Europe-focused biopharma fund"
    },
    {
      "label": "Fierce Biotech: Jeito Capital has hailed the $1.2 billion it has secured as the “largest raise ever achieved” by an independent biopharma-focused European fund."
    }
  ],
  "trend_status": "flat",
  "trend_sparkline": "▁▁",
  "trend_points_n": 0,
  "trend_window": {
    "lookback_days": 14,
    "max_points": 36,
    "value_key": null
  },
  "llm_status": "accepted",
  "llm_meta": {
    "model": "gpt-4.1-mini-2025-04-14",
    "prompt_version": "enrich_v3",
    "input_hash": "cba76e60a59f6121bf204adbd7dd734b0028fdadbe0e4ff4aee6c23b3589b83b",
    "updated_at": "2026-04-09T05:07:36.217102+00:00",
    "llm_metadata": {
      "env": "prod",
      "host": "34aa513340fd",
      "stage": "signals.enrich",
      "run_id": "95e62395-9529-470f-b806-302c8d8781d5",
      "tenant": "biotech",
      "service": "api",
      "pipeline": "pipeline_run",
      "correlation_id": "f41a6b13-7bbd-4d02-938a-e1ad958c64c9"
    }
  },
  "story_id": "d49f9655-c06c-4cb4-92b8-249c05a8b546",
  "public_surface": {
    "eligible_for_flagship_sample": true,
    "eligible_for_top_public_brief": true,
    "eligible_for_public_index": false,
    "eligible_only_for_lower_or_internal_surfaces": false,
    "public_rank_score": 12,
    "structural_priority": true,
    "mostly_social": false,
    "community_chatter": false,
    "reader_label": null,
    "excluded_reasons": [],
    "source_signals": {
      "post_count": 3,
      "unique_origins": 3,
      "source_types_count": 1,
      "independent_non_social_count": 3,
      "social_source_count": 0,
      "non_social_source_count": 0,
      "why_now_count": 3,
      "why_it_matters_count": 3
    }
  },
  "current_cycle_open": false
}

• Signals and storylines feed endpoints with filtering and rate limits
• Briefing delivery endpoints for integrations
• Evidence link payloads for auditability

• Route top stories into Slack or Teams for morning and evening desk updates.
• Sync storyline evidence into Notion, Airtable, or internal research trackers.
• Feed metrics into BI dashboards for momentum, concentration, and source mix monitoring.

Quick start endpoints: /v1/feed/stories, /v1/signals, /v1/storylines/search, /v1/briefings/latest.

For product access, see Pricing.